Back to search
Non-ischemic Dilated Cardiomyopathy
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Non-ischemic Dilated Cardiomyopathy trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Non-ischemic Dilated Cardiomyopathy trials you may qualify forThe purpose of this study is to evaluate the safety and effectiveness of an experimental drug called human allogeneic mesenchymal stem cell therapy.
Patients with idiopathic dilated cardiomyopathy in heart failure (NYHA class III - IV) with a baseline left ventricular ejection fraction between ≥25% and ≤35%,…
Non-dilated left ventricular cardiomyopathy (NDLVC), a newly defined cardiomyopathy subtype characterized by non-ischemic myocardial abnormalities without left…
The goal of the current research is to develop personalized risk prediction for functional mitral regurgitation (FMR) patients through explainable unsupervised…
Heart failure (HF) is the most common nosology encountered in clinical practice. Its incidence and prevalence increase exponentially with increasing age and it…
Risk stratification for sudden cardiac death (SCD) in patients with non-ischemic cardiomyopathy (NICM) remains suboptimal. Although current guidelines rely on s…
Heart muscle disorders are a common cause of heart failure: a life-threatening condition that can cause dangerous abnormal heart rhythms (arrhythmia) and a buil…
Research questions: The value of primary prevention implantable cardioverter-defibrillator implantation (ICD) therapy in patients with non-ischemic cardiomyopat…
This study explores the effects of combined aerobic and resistance exercise in patients with non-ischemic dilated cardiomyopathy (NIDCM). In a six-week randomiz…